139 results on '"Catena, Laura"'
Search Results
2. A resource for the world?
3. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues
4. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study
5. La difusión y revisión del marxismo en América Latina: José María Aricó y el grupo Pasado y Presente
6. Historia del Socialismo Internacional
7. Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges
8. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study
9. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
10. The future of the wine industry: overlapping insights from international leaders
11. Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?
12. The role of Geriatric screening tool (G8) in predicting side effect in older patients during therapy with aromatase inhibitor
13. MERKEL CELL CARCINOMA AFTER LIVER TRANSPLANTATION: A CASE REPORT
14. RENAL CELL CANCER AND SORAFENIB: SKIN TOXICITY AND TREATMENT OUTCOME
15. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: A Phase III Study
16. Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women
17. Update on the treatment of neuroendocrine tumors
18. ELDERLY PATIENTS WITH ADVANCED BREAST CANCER: SAFETY AND ACTIVITY OF CAPECITABINE
19. MEDICAL TREATMENT OF NEUROENDOCRINE TUMORS (NETs) WITH OXALIPLATIN AND CAPECITABINE: AN I.T.M.O. GROUP STUDY
20. Medical treatment of advanced and well differentiated neuroendocrine tumours (NETs)
21. Advances in diagnosis and therapy of neuroendocrine tumors
22. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma
23. ANASTROZOLE IN POST-MENOPAUSAL ADVANCED BREAST CANCER (ABC) PATIENTS: EFFECTS ON STEROIDS AND BONE METABOLISM
24. CAPECITABINE IN ELDERLY PATIENTS WITH ADVANCED BREAST CANCER
25. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors
26. Long-Lasting Exceptional Radiological Complete Response after Treatment with Eribulin in a Patient with Triple-Negative Breast Cancer with Liver Involvement
27. Pact of silence: cultural perspectives of disclosure to terminal patient
28. Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update
29. Abstract LB-256: Impact of metformin on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNETs) receiving everolimus and/or somatostatin analogues: A sensitivity analysis of the PRIME-NET (pancreatic multicentric, retrospective, italian metformin) study
30. La recepción de la obra de Isaac Deutscher por los trotskistas norteamericanos: un capítulo en la historia de la Cuarta Internacional
31. Everolimus in combination with Octreotide LAR in first line setting for patients with neuroendocrine tumors (I.T.M.O. study): A 5-years update.
32. Climate Change: Field Reports from Leading Winemakers
33. The socio-economic formation concept in José María Aricó’s work: a comparison with Marxist sources
34. Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update.
35. Phase II study of everolimus in combination with octreotide LAR in first line setting for patients with neuroendocrine tumors (I.T.M.O. study): A 4-year update.
36. Anarquismo y la emancipación de la mujer: El movimiento anarquista en Argentina y Nuestra Tribuna (1922-1925)
37. Updated overall survival and time to progression results in NETs treated with everolimus combination with octreotide LAR as first-line treatment.
38. Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group.
39. Combinational chemotherapy and radiotherapy
40. 10. Perspectives in the Development of Novel Treatment Approaches
41. Common Diagnostic Challenges in the Histopathologic Diagnosis of Neuroendocrine Lung Tumors: A Case Report
42. Pitfalls in the Diagnosis of Neuroendocrine Tumors: Atypical Clinical and Radiological Findings as Cause of Medical Mistakes
43. The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters: an observational study
44. 1415: Active Surveillance for Early Prostate Cancer: Initial Results
45. Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell Carcinoma
46. Pulmonary Carcinoid Tumours: Indolent but Not Benign
47. Kit Protein (CD 117) and Proliferation Index (Ki-67) Evaluation in Well and Poorly Differentiated Neuroendocrine Tumors
48. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
49. Neuroendocrine Tumors of the Larynx: A Clinical Report and Literature Review
50. Case Report of Synchronous Multicentric Osteosarcoma and Review of the Literature: The Importance of Autopsy for Diagnosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.